EPS, a CRO based in Tokyo, Japan, has chosen Bioclinica’s COMPASS technology and professional services as its risk-based monitoring (RBM) solution for clinical trials in Japan. EPS President and Representative Director Hisashi Tanaka said in a release that the company wants to implement effective RBM services consistent with global regulatory authority initiatives. The COMPASS solution was chosen for many reasons, including a library of 44 standard KRIs and an ability to add additional custom KRIs; tracking and visualization at the study and site level, and robust alert and action recommendations.
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.